Cargando…
Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant
Posttransplant vaccination targeting residual disease is an immunotherapeutic strategy to improve antigen-specific immune responses and prolong disease-free survival after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We conducted a phase 1 vaccine trial to determine the saf...
Autores principales: | Chung, David J., Sharma, Sneh, Rangesa, Madhumitha, DeWolf, Susan, Elhanati, Yuval, Perica, Karlo, Young, James W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905697/ https://www.ncbi.nlm.nih.gov/pubmed/35100339 http://dx.doi.org/10.1182/bloodadvances.2021005941 |
Ejemplares similares
-
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
por: Aaroe, Ashley, et al.
Publicado: (2023) -
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023) -
Bisphosphonates as antimyeloma drugs
por: Modi, N D, et al.
Publicado: (2012) -
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
por: Vo, Manh-Cuong, et al.
Publicado: (2018) -
Langerhans cell histiocytosis – a case report
por: Jeunon, Thiago, et al.
Publicado: (2012)